Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
July 25 2024 - 8:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its
second quarter 2024 financial results on Thursday, August 1, 2024
after the markets close. Management will conduct a conference call
and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss
the financial results and to provide a business update.
Dial-in InformationU.S. Dial-in
Number: (888) 317-6003International Dial-in Number: (412)
317-6061Conference ID: 7023126
Replay InformationU.S. Dial-in
Number: (877) 344-7529Replay International Dial-in Number: (412)
317-0088Conference ID: 3907883
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online at
www.lexpharma.com/events, with a webcast replay accessible for 14
days after the call.
About Lexicon
Pharmaceuticals Lexicon is a biopharmaceutical
company with a mission of pioneering medicines that transform
patients’ lives. Through its Genome5000™ program, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon is commercially launching one of these
medicines, INPEFA® (sotagliflozin) in the United States, and has a
pipeline of other promising drug candidates in discovery and
clinical and preclinical development in neuropathic pain, diabetes
and metabolism and other indications. For additional
information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management’s current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including Lexicon’s ability to meet its
capital requirements, successfully commercialize INPEFA in heart
failure on the timeline and/or at the prices currently contemplated
or at all, conduct preclinical and clinical development and obtain
necessary regulatory approvals of sotagliflozin (in other
indications), LX9211, LX9851 and its other drug candidates on its
anticipated timelines, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates. Any of these risks, uncertainties and
other factors may cause Lexicon’s actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such important
factors is contained under “Risk Factors” in Lexicon’s annual
report on Form 10-K for the year ended December 31, 2023 and other
subsequent disclosure documents filed with the Securities and
Exchange Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of
new information, future events or otherwise.
For Investor
Inquiries: Lisa DeFrancesco Lexicon
Pharmaceuticals,
Inc. lexinvest@lexpharma.com
For Media Inquiries:Alina
CocuzzaLexicon Pharmaceuticals, Inc.acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Aug 2023 to Aug 2024